Acute intermittent porphyria
Other Names: AIP; Porphobilinogen deaminase deficiency; PBGD deficiency; Uroporphyrinogen synthase deficiency; UPS deficiency; Porphyria, Swedish type; Hydroxymethylbilane synthase deficiency; HMBS deficiency
Acute intermittent porphyria (AIP) is one of the liver (hepatic) porphyrias. AIP is caused by low levels of porphobilinogen deaminase (PBGD), an enzyme also often called hydroxymethylbilane synthase. The low levels of PBGD are generally not sufficient to cause symptoms; however, activating factors such as hormones, drugs, and dietary changes may trigger symptoms. Although most individuals with AIP never develop symptoms, symptomatic individuals typically present with abdominal pain with nausea.
AIP is caused by the deficiency of an enzyme called porphobilinogen deaminase (PBGD), also known as hydroxymethylbilane synthase (HMBS) and formerly known as uroporphyrinogen I-synthase. The deficiency of PBGD is caused by a mutation in the ''HMBS''gene . The HMBS gene is the only gene known to be associated with AIP. However, the deficiency of PBGD alone is not enough to cause AIP. Other activating factors (e.g.,harmones, drugs, dietary changes) must also be present.
Diagnosis of AIP is suspected in individuals with otherwise unexplained severe, acute abdominal pain without physical signs. The finding of increased levels of delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in urine establishes that one of the acute porphyrias is present. If PBGD is deficient in normal red blod cells, the diagnosis of AIP is established. The diagnosis is confirmed in individuals with a disease-causing mutation in the HMBSgene , the only gene known to be associated with AIP, which encodes the erythrocyte hydroxymethylbilane synthase .
Molecular genetic testing of the HMBS gene detects more than 98% of affected individuals and is available in clinical laboratories.
Treatment of AIP may vary based on the trigger of the attack and the symptoms present. Treatment may include stopping medications that cause or worsen the symptoms, treating any infections which may be present, administration of pain medication, monitoring fluid balance and/or correcting electrolyte disturbances, monitoring neurologic status and administering respiratory support. Mild attacks can be manged with increased caloric intake and fluid replacement. Recurrent acute attacks should be managed by a porphyria specialist. Hospitalization is often necessary.
Panhematin, an intravenous medication used to correct heme deficiency, may also be prescribed.
The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition.
- Hemin (Brand name: Panhematin)
Latest research - Acute intermittent porphyria
NIH genetic and rare disease info
Acute intermittent porphyria is a rare disease.